Imaging cellular receptors in breast cancers: An overview

Current Pharmaceutical Biotechnology

Volumn 12, Issue 4, 2011, Pages 508-527

  Sekar, Thillai V ^a   Dhanabalan, Aradhana ^a   Paulmurugan, Ramasamy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Molecular imaging; Optical imaging; PET; Reporter gene

Indexed keywords

ANDROGEN RECEPTOR; BIOLUMINESCENT PROTEIN; CELL RECEPTOR; CHEMOKINE RECEPTOR; CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORESCENT PROTEIN; FOLATE RECEPTOR; MONOCLONAL ANTIBODY; NEUROPEPTIDE Y RECEPTOR; PEPTIDES AND PROTEINS; PROGESTERONE RECEPTOR; RADIOLIGAND; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CARCINOGENESIS; DRUG EFFICACY; ESTROGEN THERAPY; HUMAN; METASTASIS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; RECEPTORS, STEROID; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79953793951     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795164039     Document Type: Review

References (115)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics. CA Cancer J. Clin. 2009, 59, 225-249.
2. United states cancer statistics: 1996-2006 incidence and mortality web-based report. Center for Disease Control and Prevention, 2010.
3. Borgquist, S.; Wirfalt, E.; Jirstrom, K.; Anagnostaki, L.; Gullberg, B.; Berglund, G.; Manjer, J.; Landberg, G. Diet and body constitution in relation to subgroups of breast cancer defined by tumour grade, proliferation and key cell cycle regulators. Breast Cancer Res., 2007, 9, R11.
4. Osborne, C. K.; Shou, J.; Massarweh, S.; Schiff, R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res., 2005, 11, 865s-870s.
5. Carey, L. A.; Perou, C. M.; Livasy, C. A.; Dressler, L. G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M. A.; Tse, C. K.; Edmiston, S.; Deming, S. L.; Geradts, J.; Cheang, M. C.; Nielsen, T. O.; Moorman, P. G.; Earp, H. S.; Millikan, R. C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295, 2492-2502.
6. Iwao, K.; Miyoshi, Y.; Egawa, C.; Ikeda, N.; Noguchi, S. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int. J. Cancer, 2000, 88, 733-736.
7. Roger, P.; Sahla, M. E.; Makela, S.; Gustafsson, J. A.; Baldet, P.; Rochefort, H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res., 2001, 61, 2537-2541.
8. Kennecke, H.; Yerushalmi, R.; Woods, R.; Cheang, M. C.; Voduc, D.; Speers, C. H.; Nielsen, T. O.; Gelmon, K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol., 2010, 28, 3271-3277.
9. Thomson, V.; Pialat, J. B.; Gay, F.; Coulon, A.; Voloch, A.; Granier, A.; Guerin, J. C.; Viallon, M.; Berthezene, Y. Whole-body MRI for metastases screening: a preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images. Am. J. Clin. Oncol., 2008, 31, 285-292.
10. Weil, R. J.; Palmieri, D. C.; Bronder, J. L.; Stark, A. M.; Steeg, P. S. Breast cancer metastasis to the central nervous system. Am. J. Pathol., 2005, 167, 913-20.
11. Chen, E. I.; Hewel, J.; Krueger, J. S.; Tiraby, C.; Weber, M. R.; Kralli, A.; Becker, K.; Yates, J. R., 3rd; Felding-Habermann, B. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res., 2007, 67, 1472-1486.
12. Silva, L. D. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res., 2010, 12, R46.
13. Schwarz, C. Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer. Eur. Respir. J., 2004, 24, 728-730.
14. Qin, L. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res., 2009, 69, 3819-3827.
15. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410, 50-56.
16. Lewis-Wambi, J. S.; Kim, H. R.; Wambi, C.; Patel, R.; Pyle, J. R.; Klein-Szanto, A. J.; Jordan, V. C. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogeninduced apoptosis. Breast Cancer Res., 2008, 10, R104.
17. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Redmond, C. K.; Kavanah, M.; Cronin, W. M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 1998, 90, 1371-1388.
18. Kansra, S.; Yamagata, S.; Sneade, L.; Foster, L.; Ben-Jonathan, N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol.Cell Endocrinol., 2005, 239, 27-36.
19. Shang, Y.; Brown, M. Molecular determinants for the tissue specificity of SERMs. Science, 2002, 295, 2465-2468.
20. Johnston, S. R.; Leary, A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc), 2006,42, 441-453.
21. Molina, M. A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res., 2001, 61, 4744-4749.
22. Walshe, J. M.; Denduluri, N.; Berman, A. W.; Rosing, D. R.; Swain, S. M. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin. Breast Cancer, 2006, 6, 535-539.
23. Rowinsky, E. K.; Youssoufian, H.; Tonra, J. R.; Solomon, P.; Burtrum, D.; Ludwig, D. L. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor; Clin. Cancer Res., 2007, 13, 5549s-5555s.
24. Girdler, F.; Browell, D. A.; Cunliffe, W. J.; Shenton, B. K.; Hemming, J. D.; Scorer, P.; Young, J. R.; Brotherick, I. Use of the monoclonal antibody DAKO-ERbeta (8D5-1) to measure oestrogen receptor beta in breast cancer cells. Cytometry, 2001, 45, 65-72.
25. Kim, H.; Chaudhuri, T. R.; Buchsbaum, D. J.; Wang, D.; Zinn, K. R. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol. Cancer Ther., 2007, 6, 866-875.
26. Ponzo, M. G.; Lesurf, R.; Petkiewicz, S.; O'Malley, F. P.; Pinnaduwage, D.; Andrulis, I. L.; Bull, S. B.; Chughtai, N.; Zuo, D.; Souleimanova, M.; Germain, D.; Omeroglu, A.; Cardiff, R. D.; Hallett, M.; Park, M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. USA, 2009, 106, 12903-12908.
27. Maidment, A. D. The future of medical imaging. Radiat. Prot. Dosimetry, 2010, 139, 3-7.
28. Deshpande, N.; Needles, A.; Willmann, J. K. Molecular ultrasound imaging: current status and future directions. Clin. Radiol., 65, 567-581.
29. Ter-Pogossian, M. M.; Phelps, M. E.; Hoffman, E. J.; Mullani, N. A. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology, 1975, 114, 89-98.
30. Burt, B. M.; Humm, J. L.; Kooby, D. A.; Squire, O. D.; Mastorides, S.; Larson, S. M.; Fong, Y. Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia, 2001, 3, 189-95.
31. Torigian, D. A.; Huang, S. S.; Houseni, M.; Alavi, A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J. Clin., 2007, 57, 206-224.
32. Mintun, M. A.; Welch, M. J.; Siegel, B. A.; Mathias, C. J.; Brodack, J. W.; McGuire, A. H.; Katzenellenbogen, J. A. Breast cancer: PET imaging of estrogen receptors. Radiology, 1988, 169, 45-48.
33. Scopinaro, F.; Varvarigou, A. D.; Ussof, W.; De Vincentis, G.; Sourlingas, T. G.; Evangelatos, G. P.; Datsteris, J.; Archimandritis, S. C. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother. Radiopharm., 2002, 17, 327-335.
34. MacDonald, S. M.; Harisinghani, M. G.; Katkar, A.; Napolitano, B.; Wolfgang, J.; Taghian, A. G. Nanoparticle-enhanced MRI to evaluate radiation delivery to the regional lymphatics for patients with breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2010, 77, 1098-1104.
35. Fernandez-Guinea, O.; Andicoechea, A.; Gonzalez, L. O.; Gonzalez-Reyes, S.; Merino, A. M.; Hernandez, L. C.; Lopez-Muniz, A.; Garcia-Pravia, P.; Vizoso, F. J. Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinicopathological and biological factors in invasive breast cancer. BMC Cancer, 2010, 10, 8.
36. Szabo, B. K.; Aspelin, P.; Kristoffersen Wiberg, M.; Tot, T.; Bone, B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur. Radiol., 2003, 13, 2425-2435.
37. Weissleder, R.; Pittet, M. J. Imaging in the era of molecular oncology. Nature, 2008, 452, 580-9.
38. Goldenberg, D. M.; Preston, D. F.; Primus, F. J.; Hansen, H. J. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res., 1974, 34, 1-9.
39. Goldenberg, D. M.; Sharkey, R. M. Novel radiolabeled antibody conjugates. Oncogene, 2007, 26, 3734-3744.
40. Artemov, D.; Mori, N.; Ravi, R.; Bhujwalla, Z. M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res., 2003, 63, 2723-2727.
41. Tang, Y.; Wang, J.; Scollard, D. A.; Mondal, H.; Holloway, C.; Kahn, H. J.; Reilly, R. M. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)Intrastuzumab (Herceptin) Fab fragments. Nucl. Med. Biol., 2005, 32, 51-58.
42. Benoit, G.; Cooney, A.; Giguere, V.; Ingraham, H.; Lazar, M.; Muscat, G.; Perlmann, T.; Renaud, J. P.; Schwabe, J.; Sladek, F.; Tsai, M. J.; Laudet, V. International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev., 2006, 58, 798-836.
43. Dahlman-Wright, K.; Cavailles, V.; Fuqua, S. A.; Jordan, V. C.; Katzenellenbogen, J. A.; Korach, K. S.; Maggi, A.; Muramatsu, M.; Parker, M. G.; Gustafsson, J. A. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev., 2006, 58, 773-781.
44. Klein-Hitpass, L.; Tsai, S. Y.; Greene, G. L.; Clark, J. H.; Tsai, M. J.; O'Malley, B. W. Specific binding of estrogen receptor to the estrogen response element; Mol. Cell Biol., 1989, 9, 43-49.
45. Iwase, H. Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer, 2003, 10, 89-96.
46. Safe, S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions; Vitam. Hormone, 2001, 62, 231-252.
47. Taylor, A.H.; Al-Azzawi, F. Immunolocalisation of oestrogen receptor beta in human tissues; J. Mol. Endocrinol., 2000, 24, 145-155.
48. Jonson, S. D.; Bonasera, T. A.; Dehdashti, F.; Cristel, M. E.; Katzenellenbogen, J. A.; Welch, M. J. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes. Nucl. Med. Biol., 1999, 26, 123-130.
49. Inoue, T.; Kim, E. E.; Wallace, S.; Yang, D. J.; Wong, F. C.; Bassa, P.; Cherif, A.; Delpassand, E.; Buzdar, A.; Podoloff, D. A. Positron emission tomography using [18F] fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother. Radiopharm., 1996, 11, 235-245.
50. Strijckmans, K. The isochronous cyclotron: principles and recent developments. Comput. Med. Imaging Graph, 2001, 25, 69-78.
51. Kiesewetter, D. O.; Kilbourn, M. R.; Landvatter, S. W.; Heiman, D. F.; Katzenellenbogen, J. A.; Welch, M. J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J. Nucl. Med., 1984, 25, 1212-1221.
52. Peterson, L. M.; Mankoff, D. A.; Lawton, T.; Yagle, K.; Schubert, E. K.; Stekhova, S.; Gown, A.; Link, J. M.; Tewson, T.; Krohn, K. A. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J. Nucl. Med., 2008, 49, 367-374.
53. Kumar, P.; Mercer, J.; Doerkson, C.; Tonkin, K.; McEwan, A. J. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J. Pharm. Pharm. Sci., 2007, 10, 256s-265s.
54. Linden, H. M.; Stekhova, S. A.; Link, J. M.; Gralow, J. R.; Livingston, R. B.; Ellis, G. K.; Petra, P. H.; Peterson, L. M.; Schubert, E. K.; Dunnwald, L. K.; Krohn, K. A.; Mankoff, D. A. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol., 2006, 24, 2793-2799.
55. Osborne, J. R.; Port, E.; Gonen, M.; Doane, A.; Yeung, H.; Gerald, W.; Cook, J. B.; Larson, S. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J. Nucl. Med., 2010, 51, 543-550.
56. Buck, A.; Schirrmeister, H.; Kuhn, T.; Shen, C.; Kalker, T.; Kotzerke, J.; Dankerl, A.; Glatting, G.; Reske, S.; Mattfeldt, T. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 1317-1323.
57. Mavi, A.; Cermik, T. F.; Urhan, M.; Puskulcu, H.; Basu, S.; Yu, J. Q.; Zhuang, H.; Czerniecki, B.; Alavi, A. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J. Nucl. Med., 2007, 48, 1266-1272.
58. Seimbille, Y.; Benard, F.; Rousseau, J.; Pepin, E.; Aliaga, A.; Tessier, G.; van Lier, J. E. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alphaposition of fulvestrant (faslodex; ICI 182,780). Nucl. Med. Biol., 2004, 31, 691-698.
59. Lahorte, C.; Slegers, G.; Philippe, J.; Van de Wiele, C.; Dierckx, R. A. Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V. Biomol. Eng., 2001, 17, 51-53.
60. Van de Wiele, C.; Cocquyt, V.; Vanden Broecke, R.; De Vos, F.; Van Belle, S.; Dhaene, K.; Slegers, G.; Dierckx, R. A. Iodinelabeled tamoxifen uptake in primary human breast carcinoma. J. Nucl. Med., 2001, 42, 1818-1820.
61. Weissleder, R.; Ntziachristos, V. Shedding light onto live molecular targets. Nat. Med., 2003, 9, 123-128.
62. Luker, G. D.; Luker, K. E. Optical imaging: current applications and future directions. J. Nucl. Med., 2008, 49, 1-4.
63. Di Lorenzo, D.; Rando, G.; Ciana, P.; Maggi, A. Molecular imaging, an innovative methodology for whole-body profiling of endocrine disrupter action. Toxicol. Sci., 2008, 106, 304-311.
64. Kim, S. B.; Sato, M.; Tao, H. Molecular tension-indexed bioluminescent probe for determining protein-protein interactions; Bioconjug. Chem., 2009, 20, 2324-2330.
65. Arguello, F.; Baggs, R. B.; Frantz, C. N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res., 1988, 48, 6876-6881.
66. Yoneda, T.; Sasaki, A.; Mundy, G. R. Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treat., 1994, 32, 73-84.
67. Wetterwald, A.; van der Pluijm, G.; Que, I.; Sijmons, B.; Buijs, J.; Karperien, M.; Lowik, C. W.; Gautschi, E.; Thalmann, G. N.; Cecchini, M. G. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am. J. Pathol., 2002, 160, 1143-1153.
68. Paulmurugan, R.; Gambhir, S. S. An intramolecular folding sensor for imaging estrogen receptor-ligand interactions. Proc. Natl. Acad. Sci. USA, 2006, 103, 15883-15888.
69. Ciana, P. In vivo imaging of transcriptionally active estrogen receptors. Nat. Med., 2003, 9(1), 82-86.
70. Greene, G. L. In vivo imaging reveals estrogen receptor's hidden personality. Nat. Med., 2003, 9, 22-23.
71. Hochberg, R. B. Iodine-125--labeled estradiol: a gamma-emitting analog of estradiol that binds to the estrogen receptor. Science, 1979, 205, 1138-1140.
72. Ali, H.; Rousseau, J.; Ghaffari, M. A.; van Lier, J. E. Synthesis, receptor binding, and tissue distribution of 7 alpha-and 11 betasubstituted (17 alpha,20E)-and (17 alpha,20Z)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17-diols. J. Med. Chem., 1991, 34, 854-860.
73. Skaddan, M. B.; Wust, F. R.; Jonson, S.; Syhre, R.; Welch, M. J.; Spies, H.; Katzenellenbogen, J. A. Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7alpha-substituted estradiol complexes. Nucl. Med. Biol., 2000, 27, 269-278.
74. Ouellet, R.; Rousseau, J.; Brasseur, N.; van Lier, J. E.; Diksic, M.; Westera, G. Synthesis, receptor binding, and target-tissue uptake of carbon-11 labeled carbamate derivatives of estradiol and hexestrol. J. Med. Chem., 1984, 27, 509-513.
75. Pomper, M. G.; Van Brocklin, H.; Thieme, A. M.; Thomas, R. D.; Kiesewetter, D. O.; Carlson, K. E.; Mathias, C. J.; Welch, M. J.; Katzenellenbogen, J. A. 11 beta-methoxy-, 11 beta-ethyl-and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J. Med. Chem., 1990, 33, 3143-3155.
76. VanBrocklin, H. F.; Carlson, K. E.; Katzenellenbogen, J. A.; Welch, M. J. 16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. J. Med. Chem., 1993, 36, 1619-1629.
77. Seimbille, Y. E.; Ali, H.; Benard, F.; van Lier, J. E. Synthesis of a new series of F-18 labeled 7-substituted estradiol derivatives for PET imaging of estrogen receptor densities in breast cancer. J. Nucl. Med., 2002, 43, 364-365.
78. Yang, D. J.; Li, C.; Kuang, L. R.; Price, J. E.; Buzdar, A. U.; Tansey, W.; Cherif, A.; Gretzer, M.; Kim, E. E.; Wallace, S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci., 1994, 55(1), 53-67.
79. Neto, C.; Oliveira, M. C.; Gano, L.; Marques, F.; Santos, I.; Morais, G. R.; Yasuda, T.; Thiemann, T.; Botelho, F.; Oliveira, C. F. Radioiodinated ligands for the estrogen receptor: effect of different 7-cyanoalkyl chains on the binding affinity of novel iodovinyl-6-dehydroestradiols. Appl. Radiat. Isot, 2009, 67, 301-307.
80. Hochberg, R. B.; Zielinski, J. E.; Duax, W. L.; Strong, P. The molecular structure of 16 alpha-iodo-17 beta-estradiol, a high affinity ligand for the estrogen receptor. J. Steroid Biochem., 1986, 25, 615-618.
81. Pavlik, E. J.; Nelson, K.; Gallion, H. H.; van Nagell, J. R. Jr.; Donaldson, E. S.; Shih, W. J.; Spicer, J. A.; Preston, D. F.; Baranczuk, R. J.; Kenady, D. E. Characterization of high specific activity [16 alpha-123I]Iodo-17 beta-estradiol as an estrogen receptor-specific radioligand capable of imaging estrogen receptorpositive tumors. Cancer Res., 1990, 50, 7799-7805.
82. Schober, O.; Scheidhauer, K.; Jackisch, C.; Schicha, H.; Smolarz, K.; Bolte, A.; Reiners, C.; Hoffken, K.; Biersack, H. J.; Briele, B.Breast cancer imaging with radioiodinated oestradiol. Lancet, 1990, 335, 1522.
83. Symes, E. K.; Coulson, W. F.; Ralphs, D. N. The synthesis of 16 alpha-[131I]iodo-oestradiol and evaluation of its use as a ra diotracer for oestrogen receptor positive breast tumours. J. Steroid Biochem., 1985, 22, 155-160.
84. Spradau, T. W.; Edwards, W. B.; Anderson, C. J.; Welch, M. J.; Katzenellenbogen, J. A. Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide. Nucl. Med. Biol., 1999, 26, 1-7.
85. Unak, P.; Enginar, H.; Biber, F. Z.; Lambrecht, F. Y.; Aslani, M. A.; Ozkilic, H. A correlative study between 99mTc-ESTCPTA and 99mTc-MIBI in rats. Appl. Radiat. Isot., 2002, 57, 733-742.
86. Hunter, D. H.; Luyt, L. G. Single isomer technetium-99m tamoxifen conjugates. Bioconjug. Chem., 2000, 11, 175-181.
87. Ali, H.; Rousseau, J.; Diksic, M.; van Lier, J. E. Synthesis, receptor binding and target-tissue uptake of carbon-11-labeled carbamate derivatives of estradiol and hexestrol. Int. J. Rad. Appl. Instrum. B., 1992, 19, 175-182.
88. Meyers, M. J.; Sun, J.; Carlson, K. E.; Marriner, G. A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem., 2001, 44, 4230-4251.
89. Moon, B. S.; Carlson, K. E.; Katzenellenbogen, J. A.; Choi, T. H.; Chi, D. Y.; Kim, J. Y.; Cheon, G. J.; Koh, H. Y.; Lee, K. C.; An, G. Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents. Bioorg. Med. Chem., 2009, 17, 3479-3488.
90. Ochiai, I.; Matsuda, K.; Nishi, M.; Ozawa, H.; Kawata, M. Imaging analysis of subcellular correlation of androgen receptor and estrogen receptor alpha in single living cells using green fluorescent protein color variants. Mol. Endocrinol., 2004, 18, 26-42.
91. Stenoien, D. L.; Patel, K.; Mancini, M. G.; Dutertre, M.; Smith, C. L.; O'Malley, B. W.; Mancini, M. A. FRAP reveals that mobility of oestrogen receptor-alpha is ligand-and proteasome-dependent. Nat. Cell Biol., 2001, 3, 15-23.
92. Kochanny, M. J.; VanBrocklin, H. F.; Kym, P. R.; Carlson, K. E.; O'Neil, J. P.; Bonasera, T. A.; Welch, M. J.; Katzenellenbogen, J. A. Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J. Med. Chem., 1993, 36, 1120-1127.
93. Verhagen, A.; Studeny, M.; Luurtsema, G.; Visser, G. M.; De Goeij, C. C.; Sluyser, M.; Nieweg, O. E.; Van der Ploeg, E.; Go, K. G.; Vaalburg, W. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl. Med. Biol., 1994, 21, 941-952.
94. Zhou, D.; Carlson, K. E.; Katzenellenbogen, J. A.; Welch, M. J. Bromine-and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J. Med. Chem., 2006, 49, 4737-4744.
95. Dehdashti, F.; McGuire, A. H.; Van Brocklin, H. F.; Siegel, B. A.; Andriole, D. P.; Griffeth, L. K.; Pomper, M. G.; Katzenellenbogen, J. A.; Welch, M. J. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J. Nucl. Med., 1991, 32, 1532-1537.
96. Zhou, H. B.; Lee, J. H.; Mayne, C. G.; Carlson, K. E.; Katzenellenbogen, J. A. Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. J. Med. Chem., 2010, 53, 3349-3360.
97. Lee, J. H.; Zhou, H. B.; Dence, C. S.; Carlson, K. E.; Welch, M. J.; Katzenellenbogen, J. A. Development of [f-18]fluorine-substituted tanaproget as a progesterone receptor imaging agent for positron emission tomography. Bioconjug. Chem., 2010, 21, 1096-1104.
98. Huber, M. H.; Lippman, S. M.; Hong, W. K. Chemoprevention of head and neck cancer. Semin. Oncol., 1994, 21, 366-375.
99. Marth, C.; Bock, G.; Daxenbichler, G. Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. J. Natl. Cancer Inst., 1985, 75, 871-875.
100. Macejova, D.; Baranova, M.; Liska, J.; Brtko, J. Expression of nuclear hormone receptors, their coregulators and type I iodothyronine 5'-deiodinase gene in mammary tissue of nonlactating and postlactating rats. Life Sci., 2005, 77, 2584-2593.
101. Giguere, V.; Evans, R. M. Identification of receptors for retinoids as members of the steroid and thyroid hormone receptor family. Methods Enzymol., 1990, 189, 223-232.
102. So, M. K.; Kang, J. H.; Chung, J. K.; Lee, Y. J.; Shin, J. H.; Kim, K. I.; Jeong, J. M.; Lee, D. S.; Lee, M. C. In vivo imaging of retinoic acid receptor activity using a sodium/iodide symporter and luciferase dual imaging reporter gene. Mol. Imaging, 2004, 3, 163-171.
103. Chen, C.; Peng, J.; Xia, H.; Wu, Q.; Zeng, L.; Xu, H.; Tang, H.; Zhang, Z.; Zhu, X.; Pang, D.; Li, Y. Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity. Nanotechnology, 2010, 21, 95-101.
104. Morgan, N. Y.; English, S.; Chen, W.; Chernomordik, V.; Russo, A.; Smith, P. D.; Gandjbakhche, A. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad. Radiol., 2005, 12, 313-323.
105. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24, 389-427.
106. Reubi, C.; Gugger, M.; Waser, B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 855-862.
107. van Eijck, C. H.; Krenning, E. P.; Bootsma, A.; Oei, H. Y.; van Pel, R.; Lindemans, J.; Jeekel, J.; Reubi, J. C.; Lamberts, S. W. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet, 1994, 343, 640-643.
108. Dagar, S.; Sekosan, M.; Rubinstein, I.; Onyuksel, H. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res. Treat., 2001, 65, 49-54.
109. Chanda, N.; Shukla, R.; Katti, K. V.; Kannan, R. Gastrin releasing protein receptor specific gold nanorods: breast and prostate tumor avid nanovectors for molecular imaging. Nano. Lett., 2009, 9, 1798-1805.
110. Reubi, J. C.; Gugger, M.; Waser, B.; Schaer, J. C. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res., 2001, 61, 4636-4641.
111. Guerin, B.; Dumulon-Perreault, V.; Tremblay, M. C.; Ait-Mohand, S.; Fournier, P.; Dubuc, C.; Authier, S.; Benard, F. [Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging. Bioorg. Med. Chem. Lett., 2010, 20, 950-953.
112. Luker, K. E.; Gupta, M.; Luker, G. D. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J., 2009, 23, 823-834.
113. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 1994, 73, 2432-2443.
114. Parker, N.; Turk, M. J.; Westrick, E.; Lewis, J. D.; Low, P. S.; Leamon, C. P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem., 2005, 338, 284-293.
115. Hartmann, L. C.; Keeney, G. L.; Lingle, W. L.; Christianson, T. J.; Varghese, B.; Hillman, D.; Oberg, A. L.; Low, P. S. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer, 2007, 121, 938-942.